Pain scale

Nimbus Therapeutics Announces Expansion of Its Immunology Drug Discovery Pipeline

Retrieved on: 
Friday, January 5, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Biology, Conference, Family, Partnership, Drug discovery, Metabolism, WRN, IND, Drug design, Werner syndrome helicase, Pain scale, MBA, Therapy, Eli Lilly and Company, HPK1, DSM-IV codes, AMPK, Investment, Patient, TYK2, Pharmaceutical industry

Nimbus Therapeutics , LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, announced the advancement and expansion of its pipeline with the addition of discovery programs targeting innate immunity pathways.

Key Points: 
  • Nimbus Therapeutics , LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, announced the advancement and expansion of its pipeline with the addition of discovery programs targeting innate immunity pathways.
  • "Building on the success of our TYK2 program, we are broadening our drug discovery engine to unlock new difficult-to-drug targets with compelling biology,” said Peter Tummino, Ph.D., Chief Scientific Officer of Nimbus.
  • “SIK and cGAS are critical targets in highly prevalent diseases that are well suited to Nimbus’ structure-based drug design approach.
  • Nimbus continues to expand its platform capabilities with ongoing investments in cutting-edge technology for drug discovery.

Ventus Therapeutics Initiates Clinical Testing of VENT-03, a First-in-Class, Orally Administered cGAS Inhibitor

Retrieved on: 
Wednesday, January 3, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Machine learning, Physics, Pain scale, Pharmacokinetics, Computational chemistry, Patient, Safety, Therapy, Inflammation, Pharmaceutical industry

Ventus Therapeutics , a clinical-stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform, ReSOLVETM, to develop differentiated small molecule therapeutics, announced today that the first participant has been dosed in a Phase 1 clinical trial of VENT-03, the first cGAS inhibitor to advance into clinical development.

Key Points: 
  • Ventus Therapeutics , a clinical-stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform, ReSOLVETM, to develop differentiated small molecule therapeutics, announced today that the first participant has been dosed in a Phase 1 clinical trial of VENT-03, the first cGAS inhibitor to advance into clinical development.
  • “cGAS has historically proven an elusive target despite significant industry efforts to develop a viable inhibitor.
  • We have broken that cycle with the initiation of this Phase 1 clinical trial,” said Ventus President and CEO Marcelo Bigal, M.D., Ph.D. “We are eager to advance this therapeutic candidate and bring the potential of cGAS inhibition to patients suffering from inflammatory disorders with significant unmet needs.
  • Ventus expects results from the trial in the second half of 2024.

Corner Therapeutics Announces First Publication on Proprietary Catalytic Adjuvant Platform

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Oncology, Vaccine, DC, Antigen, MBio, Lipid, Cytokine, Infection, Virus, Protein, Observation, Pain scale, Corner, B cell, Lung, Vaccination, Immune system, COVID-19, Immunity, Medicine, Cancer, Messenger, Blood, Nobel Prize, Therapy, Nobel Prize in Physiology or Medicine, Patient, Doctor of Philosophy, Physiology, LNP

Corner Therapeutics , a biotechnology company exploiting a new scientific paradigm to boost the immune response to disease, today announced the first publication detailing their proprietary Catalytic Adjuvant platform that drives strong T cell immune responses to mRNA vaccines.

Key Points: 
  • Corner Therapeutics , a biotechnology company exploiting a new scientific paradigm to boost the immune response to disease, today announced the first publication detailing their proprietary Catalytic Adjuvant platform that drives strong T cell immune responses to mRNA vaccines.
  • The enhanced T cell immunogenicity of Corner Therapeutics’ Catalytic Adjuvant platform was also observed for antibody production.
  • “This publication is an exciting milestone for Corner Therapeutics, offering the first overview of our catalytic adjuvants as tools to stimulate unprecedented vaccine immunogenicity,” said Jonathan Kagan, Ph.D., Scientific Co-founder and Advisor at Corner Therapeutics and lead author of the publication.
  • “As we continue to develop our Catalytic Adjuvant platform, we look forward to exploring its broad potential to generate lifelong immunity for patients young and old.”

Ventus Therapeutics Named a “Fierce 15” Biotech Company of 2023

Retrieved on: 
Monday, August 28, 2023
Science, Neurology, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Partnership, Doctor of Philosophy, Face, Health care, NLRP3, Lupus, Inflammation, Scleroderma, DSM-IV codes, Creativity, Patient, Novo Nordisk, Pain scale, Annual report, Therapy, Pharmaceutical industry

Ventus Therapeutics , a clinical-stage biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to develop a robust pipeline of novel medicines in immunology, inflammation, and neurology, today announced that it has been named a “Fierce 15” company in Fierce Biotech’s 2023 annual report featuring the most innovative and promising biotechnology companies in the industry.

Key Points: 
  • Ventus Therapeutics , a clinical-stage biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to develop a robust pipeline of novel medicines in immunology, inflammation, and neurology, today announced that it has been named a “Fierce 15” company in Fierce Biotech’s 2023 annual report featuring the most innovative and promising biotechnology companies in the industry.
  • Earlier this month, Ventus initiated a Phase 1 clinical trial of its most advanced program, VENT-02, an oral, brain-penetrant NLRP3 inhibitor with best-in-class potential across multiple neurological diseases, including Parkinson’s disease, Alzheimer’s disease, and refractory epilepsy.
  • In addition to VENT-02, Ventus is also rapidly advancing its first-in-class cGAS inhibitor, VENT-03, towards the clinic for development in lupus, systemic sclerosis, and other inflammatory disorders.
  • “We are honored by Fierce Biotech’s recognition of the accomplishments of the Ventus team,” said Ventus President and CEO Marcelo Bigal, M.D., Ph.D. “Our scientific development has consistently translated into value.

IRBM, Rainwater Charitable Foundation and Weill Cornell Medicine Join Forces to Progress Therapies for Neurodegenerative Disorders

Retrieved on: 
Wednesday, July 12, 2023
Vaccine, GMP, Huntington's disease, DNA, Business development, Weill Cornell Medicine, Tau, N8 Research Partnership, Therapy, Speech, Neurodegenerative disease, Dementia, Research, IRBM, Doctor of Philosophy, Tauopathy, Richard Rainwater, Organization, Frontotemporal dementia, Parkinson's disease, HIV disease progression rates, RCF, Drug discovery, Pain scale, AD, Rain, Alzheimer's disease, PSP, Pharmaceutical industry

The collaboration brings together IRBM’s capabilities in drug discovery and development, RCF’s medical research resources via the Tau Consortium, and the expertise of Weill Cornell Medicine neuroscientist Dr. Li Gan to pursue innovative therapies for neurodegenerative disorders.

Key Points: 
  • The collaboration brings together IRBM’s capabilities in drug discovery and development, RCF’s medical research resources via the Tau Consortium, and the expertise of Weill Cornell Medicine neuroscientist Dr. Li Gan to pursue innovative therapies for neurodegenerative disorders.
  • We are therefore privileged to start our work on Alzheimer’s with renowned specialists in the area: Rainwater Charitable Foundation and Weill Cornell Medicine.
  • Weill Cornell Medicine Enterprise Innovation negotiated and helped facilitate the collaboration between Dr. Gan and the RCF with the aim to support efforts to discover new therapies for debilitating neuro-degenerative diseases.
  • For more information, please visit www.irbm.com
    The Rainwater Charitable Foundation was founded by Texas investor and philanthropist Richard Rainwater in 1991 to support childhood-focused initiatives.

Ventus Therapeutics Hosts Inaugural Program Spotlight: VENT-03, a First-in-Class cGAS Inhibitor

Retrieved on: 
Monday, May 1, 2023
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, Inflammation, Biology, University of Pennsylvania Health System, Lupus, Pain scale, Dicarboxylic acid, Therapy, Patient, SLE, Medicine, Pharmaceutical industry, Dermatology

The virtual event will feature VENT-03, a first-in-class cGAS inhibitor in development for lupus and other inflammatory disorders.

Key Points: 
  • The virtual event will feature VENT-03, a first-in-class cGAS inhibitor in development for lupus and other inflammatory disorders.
  • cGAS, a highly sought-after target, is an innate immune sensor of nucleic acids that, when aberrantly activated, leads to auto-inflammation and tissue damage.
  • The pathway has been clinically validated in systemic lupus erythematosus (SLE) and is implicated in a wide range of immunological and neuroinflammatory conditions.
  • Ventus has demonstrated proof-of-mechanism with its portfolio of cGAS inhibitors in multiple disease models.

Ventus Therapeutics Provides Updates on cGAS Inhibitor Program at Keystone Symposium on Innate Immunity

Retrieved on: 
Monday, April 17, 2023
Health, Neurology, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Inflammation, Rheumatology, Lupus, MDT, Therapy, Chronic kidney disease, Drug discovery, NLRP3, SLE, Scleroderma, Organization, Biology, Photosensitivity, Poster, Pain scale, Pharmaceutical industry, Innate Immunotherapeutics

Ventus Therapeutics, Inc. , a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop differentiated small molecule therapeutics across a broad range of diseases, announced the details of two presentations to be made at the Keystone Symposium on Innate Immunity: From Innate Sensing to Adaptive Responses, being held April 16-19 in Snowbird, Utah.

Key Points: 
  • Ventus Therapeutics, Inc. , a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop differentiated small molecule therapeutics across a broad range of diseases, announced the details of two presentations to be made at the Keystone Symposium on Innate Immunity: From Innate Sensing to Adaptive Responses, being held April 16-19 in Snowbird, Utah.
  • At the 8:00AM MDT Tuesday session, Ventus Chief Scientific Officer Michael Crackower, Ph.D., will present “Structure and Computation-Based Drug Discovery in Innate Immunity.” This presentation will mark the public debut of data showcasing the potency and pharmacokinetic profile of the company’s potential first-in-class cGAS inhibitor, VENT-03.
  • Ventus’ portfolio of cGAS inhibitors have demonstrated modulation of key endpoints in models of lupus, dermal inflammation, and chronic kidney disease.
  • Additionally, Dr. Crackower will present new data on the company’s portfolio of brain-penetrant NLRP3 inhibitors in a seizure model.

Kyowa Kirin Will Present New Rocatinlimab Phase 2b Data in Atopic Dermatitis at the American Academy of Dermatology Annual Meeting 2023

Retrieved on: 
Friday, March 17, 2023
NRS, Pros, Inflammation, Dermatology Life Quality Index, Week, Chills, Sleep, Fever, American Academy, Atopic dermatitis, Common, MSAD, Pain, Kyowa Kirin, OX40, DLQI, Patient, AAD, Pain scale, Itch, American Academy of Dermatology, Annual general meeting, Nausea, Aphthous stomatitis, Immunoglobulin E, Headache, SD, TSE, Disease, Vaccine, Aluminium, Copper, Silviculture

AD affects 15-20% of children and up to 10% of adults, making it the 15th most common nonfatal disease.

Key Points: 
  • AD affects 15-20% of children and up to 10% of adults, making it the 15th most common nonfatal disease.
  • "We are pleased to share this additional data from the rocatinlimab Phase 2b study," said Yoshifumi Torii, Ph.D., Executive Officer, Vice President, Head of R&D Division of Kyowa Kirin.
  • From baseline to Week 16, percentage reductions in NRS-pruritus (p≤0.029) and NRS-SD scores (p≤0.025) were greater in the rocatinlimab groups compared with placebo.
  • The most frequent TEAEs, reported in ≥ 10% of subjects in the combined rocatinlimab groups were nasopharyngitis, worsening of AD, pyrexia and chills.

H2Ocean LLC Releases Study on The Efficacy of Sea Salt Nasal Spray on Sinusitis

Retrieved on: 
Thursday, February 9, 2023
Sinusitis, Inflammation, Paranasal sinuses, Pain scale, Skin, Nasal cavity, Pressure, CRS, Edema, Enzyme, Irritant, Patient, Congestion, Nasal spray, Red Sea, Research, Immune system, Pharmaceutical industry

H2Ocean LLC has published a clinical study on the efficacy of their sea salt-based nasal spray, Nasalzyme, which can relieve the symptoms of chronic rhinosinusitis

Key Points: 
  • CRS affects up to 12% of the global population and can cause uncomfortable symptoms such as congestion, facial pain or pressure, and nasal discharge.
  • Researchers in the study tested the efficacy of H2Ocean's sea salt-based nasal spray, Nasalzyme, on patients suffering from CRS.
  • Researchers also noted that nasal sprays can remove irritants from the nasal cavity, thin mucus, reduce edema, and decrease pathogen presence in the sinuses.
  • Since opening in 2001, H2Ocean has been an advocate for sea salt-based healthcare products as a natural, eco-friendly alternative to standard medical treatment.

Orbita Launches Solution to Transform Healthcare Website Search Functionality

Retrieved on: 
Wednesday, January 18, 2023
OpenTable, Vocabulary, Patient, Orbit (anatomy), Health, Insurance, Abdominal pain, Pain scale, Online shopping, Pharmaceutical industry

BOSTON, Jan. 18, 2023 /PRNewswire/ -- Orbita, a leading provider of intelligent virtual assistants and workflow automation for healthcare, introduced Orbita Blaze to revolutionize provider websites by combining an intuitive and user-friendly "find care" experience with the convenience of a healthcare-specific chatbot. Blaze uses conversational AI to pose questions and probe for details that help patients find what they are looking for, then guides them to the most appropriate provider and facility.

Key Points: 
  • Most healthcare websites are fraught with functionality shortfalls.
  • In fact, 78% of people who said they switched providers in 2021 did so because of poor healthcare navigation, including difficulty using digital tools like the website.
  • While 43% of patients prefer to use a provider's website search function, the process can be overwhelming and frustrating.
  • It takes the chatbot out of the bottom right-hand corner and initiates a conversational interaction from the search bar or any link on the website.